Misonix Appoints Scott Ludecker Vice President of Global Sales and Marketing

 Misonix Appoints Scott Ludecker Vice President of Global Sales and Marketing

PR Newswire

FARMINGDALE, N.Y., May 13, 2013

FARMINGDALE,N.Y., May 13, 2013 /PRNewswire/ --Misonix, Inc. (Nasdaq:MSON),
a surgical device company that designs, manufactures and markets innovative
therapeutic ultrasonic products worldwide for wound debridement, spinal
surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other
surgical applications, announced today the appointment of Scott Ludecker as
Vice President of Global Sales and Marketing.Mr. Ludecker will oversee all
sales and marketing activities for Misonix worldwide.

With more than 20 years of experience in the global medical device industry,
Scott Ludecker has a demonstrated track record of successfully commercializing
medical technology and in building and managing global sales distribution
networks. Mr. Ludecker most recently served as Vice President of Global Sales
and Marketing for BioMimetic Therapeutics, a NASDAQ-listed biotechnology
company, specializing in the development and commercialization of products
which promote the healing of musculoskeletal injury and diseases, including
orthopedic, spine, and sports medicine applications. He was responsible for
building the commercial launch strategy and the associated infrastructure to
support a global product launch for BioMimetic's regenerative medicine
platform technology, in a market estimated to exceed $1 billion annually in
the U.S. Prior to BioMimetic, Mr. Ludecker served in a variety of sales and
marketing leadership positions with Small Bone Innovations (SBi), a private
New York City-based orthopedic company specializing in small bones, and Smith
and Nephew, a leading U.K.-based global provider of orthopedic reconstruction
implants and a broad portfolio of medical instruments and supplies. Mr.
Ludecker is a graduate of Kenyon College with a Bachelor of Arts degree.

Michael A. McManus, Jr., president and chief executive officer, said, "We are
pleased to have an industry professional the caliber of Scott Ludecker join
Misonix at this critical point in the history of the Company. Scott has a
proven track record of success in many of the markets in which we operate. We
look for Scott's leadership and extensive industry experience to energize our
global sales and marketing team to become the competitive and disciplined
sales force that will increasingly drive Misonix products into surgical suites
around the world. I look forward to working closely with Scott to achieve our
strategic goals."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at

Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

Company Contact:   Investor Contacts:
Richard Zaremba    Joe Diaz
Misonix, Inc.      Lytham Partners, LLC
631-694-9555       602-889-9700
invest@misonix.com mson@lythampartners.com
www.misonix.com    www.lythampartners.com

SOURCE Misonix, Inc.

Website: http://www.misonix.com
Press spacebar to pause and continue. Press esc to stop.